TCR² Therapeutics Inc. (NasdaqGS: TCRR) Loss Submission Form

Kuznicki Law is investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP). Under the terms of the proposed transaction, shareholders of TCR² will receive 1.5117 ADS of Adaptimmune for each share of TCR² that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.

Tell Us About Your Loss
Kuznicki Law PLLC does not share your information with others. There is no other or obligation for you to submit.
Your Name*
First Last
Your Address*
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country
Your Contact Information*
Phone*
Describe the nature of your loss.*
This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.
Email
This field is for validation purposes and should be left unchanged.

TCR² Therapeutics Inc. (NasdaqGS: TCRR) Loss Submission Form

Tell Us About Your Loss

Current Cases

About Us

KUZNICKI LAW PLLC